Efficacy and Safety of Lumiracoxib 400 mg Once Daily in Acute Flares of Gout
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
This study is designed to develop our understanding of the efficacy and safety of using
lumiracoxib in the treatment of patients with acute gout. This is a multi-center,
double-blind, randomized, parallel group study comparing a single daily dose of 400 mg
lumiracoxib with the established dose of indomethacin 50 mg taken three times a day in terms
of efficacy